Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.37 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 4/20 | 0.35 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10443781 | 0.87 | ALDH1A1 (0.45) | ALDH1A1MAPTPTGS1SLC1A2SLC1A1 | |
| SCHEMBL24015558 | 0.87 | ALDH1A1 (0.45) | ALDH1A1MAPTPTGS1SLC1A2SLC1A1 | |
| SCHEMBL19246147 | 0.83 | ALDH1A1 (0.42) | ALDH1A1MAPTPTGS1SLC1A2SLC1A1 | |
| SCHEMBL19246467 | 0.83 | ALDH1A1 (0.42) | ALDH1A1MAPTPTGS1SLC1A2SLC1A1 | |
| SCHEMBL1631413 | 0.80 | ALDH1A1 (0.52) | ALDH1A1MAPTPTGS1SLC1A2SLC1A1 | |
| SCHEMBL3821550 | 0.80 | ALDH1A1 (0.52) | ALDH1A1MAPTPTGS1SLC1A2SLC1A1 | |
| SCHEMBL1769263 | 0.80 | PTGS1 (0.52) | ALDH1A1MAPTPTGS1SLC1A2SLC1A1 | |
| SCHEMBL23760539 | 0.79 | ALDH1A1 (0.38) | ALDH1A1MAPTPTGS1SLC1A2SLC1A1 | |
| Hydrochloric Acid SCHEMBL7379812 | 0.78 | ALDH1A1 (0.50) | ALDH1A1MAPTPTGS1SLC1A2SLC1A1 | |
| Hydrochloric Acid SCHEMBL23462497 | 0.78 | ALDH1A1 (0.50) | ALDH1A1MAPTPTGS1SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9376694-B2 | Method for preparing optically active amino acid using cosubstrate shuttling of transaminase | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2016-06-28 | — | — | US | claimed |
| US-20150284750-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE AMINO ACID USING COSUBSTRATE SHUTTLING OF TRANSAMINASE | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2015-10-08 | — | — | US | claimed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
| US-20230357307-A1 | CLEAVABLE CYCLIC LOOP NUCLEOTIDES FOR NANOPORE SEQUENCING | ILLUMINA, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230053449-A1 | DC-SIGN ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2023-02-23 | — | — | US | disclosed |
| EP-3613422-A1 | WOUND HEALING PROMOTER | Nahls Corporation Co., Ltd. (JP) | 2020-02-26 | — | — | EP | disclosed |
| US-9376694-B2 | Method for preparing optically active amino acid using cosubstrate shuttling of transaminase | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2016-06-28 | — | — | US | disclosed |
| US-20150284750-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE AMINO ACID USING COSUBSTRATE SHUTTLING OF TRANSAMINASE | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2015-10-08 | — | — | US | disclosed |
| WO-2007002594-A1 | COSMETIC COMPOSITIONS AND METHODS USING TRANSFORMING GROWTH FACTOR-BETA MIMICS | BHATNAGAR RAJENDRA S (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060293227-A1 | Cosmetic compositions and methods using transforming growth factor-beta mimics | BHATNAGAR RAJENDRA S | 2006-12-28 | — | — | US | disclosed |
| US-20060293228-A1 | Therapeutic compositions and methods using transforming growth factor-beta mimics | BHATNAGAR RAJENDRA S | 2006-12-28 | — | — | US | disclosed |
| US-20020123468-A1 | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-05 | — | — | US | disclosed |
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-30 | — | — | US | disclosed |
| EP-1196436-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001064678-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001040262-A1 | ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001002424-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-01-11 | — | — | WO | disclosed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0787010-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-06 | — | — | EP | disclosed |
| WO-1996012499-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230053449-A1 | DC-SIGN ANTIBODY DRUG CONJUGATES | DCUN1D4, CD14, DCUN1D3 | ALDH1A1 2550/4885MAPT 1439/4885PTGS1 4363/4885 |
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | TMPRSS15, CTRC, CPN1 | ALDH1A1 1353/4885MAPT 4425/4885PTGS1 118/4885 |
| US-20230357307-A1 | CLEAVABLE CYCLIC LOOP NUCLEOTIDES FOR NANOPORE SEQUENCING | TENT4A, TENT4B, DNTT | ALDH1A1 4509/4885MAPT 4102/4885PTGS1 4767/4885 |
| US-20020123468-A1 | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease | CES1, CYP51A1, SPINT2 | ALDH1A1 697/4885MAPT 3370/4885PTGS1 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.